In a systematic review and meta-analysis of data from EMPAREG OUTCOME, CANVAS program, and DECLARE TIMI 58 trials, SGLT2 inhibitors lowered the risk of HHF by 31%, and this risk reduction was maintained regardless of the presence of atherosclerotic cardiovascular disease (ASCVD) [34]. This evidence concerns the gene SLC5A2 and atherosclerosis.